Royalty Pharma Announces $100 million Acquisition of Royalty Rights in cardiovascular drug Omecamtiv Mecarbil from Cytokinetics

New York, NY and South San Francisco, CA - February 2, 2017 – Royalty Pharma buys royalty on worldwide sales of Omecamtiv Mecarbil. Cytokinetics agrees to exercise option to co-fund Phase 3 development program under collaboration with Amgen for increased royalty and co-promotion rights in North America.

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.